Distinguishing TP53- from PIK3CA-driven breast cancers is clinically important: TP53 mutations predominate in estrogen receptor–negative tumors and portend poor prognosis, whereas PIK3CA mutations are frequent in estrogen receptor–positive tumors and guide PI3K/mTOR–targeted therapy [21]. Here, ESR1 is linked to breast cancer.